Concord Biotech Q1 Results FY27: PAT at Rs 56 Cr for June 2026 Quarter
- August 3, 2026
- Posted by: Kunal Singla
- Category: News
Concord Biotech Q1 FY27: PAT Rs 56 Cr, +32.55% YoY. Revenue Rs 257 Cr, +26.23% YoY. Stock at Rs 1,444.4 (up 1.66%).
The Concord Biotech Q1 results FY27 show consolidated revenue of Rs 257 Cr for the quarter ended 30 June 2026, +26.23% from Rs 203 Cr in Q1 FY26, as Concord Biotech reported its numbers on 31 July 2026.
Concord Biotech posted a net profit (PAT) of Rs 56 Cr for the quarter, against Rs 42 Cr a year earlier. Shares traded around Rs 1,444.4 on the NSE, up 1.66% on the day, as investors weighed the print against trends in the pharmaceuticals sector. Here is a full breakdown of the financial highlights, key business factors, dividend status, outlook and risks.
Click Here – Get Free Investment Predictions
Concord Biotech Q1 Results FY27 Financial Highlights
The table below summarises Concord Biotech’s consolidated numbers for the quarter against the year ago period.
| Metric | Q1 FY27 (Jun 2026) | Q1 FY26 (Jun 2025) | YoY Change |
|---|---|---|---|
| Revenue | Rs 257 Cr | Rs 203 Cr | +26.23% |
| Gross Profit | Rs 64 Cr | Rs 43 Cr | +47.35% |
| Gross Profit Margin | 24.9% | 21.2% | +3.7 pts |
| Net Profit (PAT) | Rs 56 Cr | Rs 42 Cr | +32.55% |
| Net Profit Margin | 21.8% | 20.7% | +1.1 pts |
Concord Biotech Q1 FY27 Performance Analysis
The numbers show a clear topline expansion, with revenue climbing +26.23% year on year to Rs 257 Cr against Rs 203 Cr in Q1 FY26. That pace of growth is the headline positive from the release.
Profitability improved alongside the topline. Gross profit grew +47.35% year on year to Rs 64 Cr (24.9% margin), outpacing revenue growth and pointing to better cost control or a richer product mix during the quarter.
The bottom line followed through on the operating performance. Net profit increased +32.55% year on year to Rs 56 Cr, up from Rs 42 Cr in Q1 FY26, translating the quarter’s operating trends into a stronger PAT print.
Check the Univest Screener for Live Data
Concord Biotech Q1 FY27: Key Business Factors
1. Revenue Growth Trajectory
Concord Biotech reported revenue of Rs 257 Cr for the June 2026 quarter against Rs 203 Cr in the year ago period, a change of +26.23%. This pace of change is a primary swing factor behind the quarter’s numbers, and investors typically track whether it holds up in the following quarters.
2. Gross Margin and Cost Trends
Gross profit moved from Rs 43 Cr in Q1 FY26 to Rs 64 Cr in Q1 FY27, a change of +47.35%. In the pharmaceuticals sector, this line is sensitive to raw material and API cost volatility, regulatory approvals and pricing pressure in key markets, and this quarter’s numbers reflect how Concord Biotech managed that balance.
3. Bottom Line and Earnings Quality
Net profit moved from Rs 42 Cr in Q1 FY26 to Rs 56 Cr this quarter, up +32.55%. On a reported basis this is the figure that flows through to earnings per share, and it is usually the first number investors check.
Dividend Details
Specific dividend information was not confirmed as part of this results snapshot. Investors should check the official exchange filing on the NSE or BSE website, or track the Univest Screener, for the latest dividend announcement, record date and payment date from Concord Biotech.
Concord Biotech Outlook for FY27
This quarter sets the tone for the rest of FY27. If the growth in revenue and improvement in net profit persist, analysts are likely to revisit their FY27 estimates for Concord Biotech. Investors should also watch input costs and demand trends in the pharmaceuticals sector through the year.
Concord Biotech Stock Performance After the Results
Concord Biotech shares traded around Rs 1,444.4 on the NSE, up 1.66% around the time the results were in focus. The 52 week trading range was not confirmed as part of this snapshot; investors can check the live 52 week high and low, along with technical levels, on the Univest Screener before making any trading decision.
Download the Univest iOS App or Univest Android App to track Concord Biotech live share price and upcoming quarterly results.
Key Risks
Investors reading through Concord Biotech’s numbers should also weigh the following risks.
1. Margin and Input Cost Risk
Being in the pharmaceuticals sector, Concord Biotech remains exposed to raw material and API cost volatility, regulatory approvals and pricing pressure in key markets. A reversal in the trend seen this quarter could pressure margins in coming quarters.
2. Execution and Working Capital Risk
Execution risk around working capital, receivables and order timelines can cause quarter to quarter volatility in reported numbers, so this quarter’s trends should be read over a few quarters rather than in isolation.
3. Macro and Sector Risk
Broader macro factors including interest rates, currency movements and demand cycles in the pharmaceuticals sector could influence how sustainable this quarter’s trends prove to be over FY27.
Conclusion
The Concord Biotech Q1 results FY27 show revenue of Rs 257 Cr and Rs 56 Cr for the quarter, against Rs 203 Cr and Rs 42 Cr in Q1 FY26. Revenue growth and a stronger bottom line were the two moving parts this quarter. Investors tracking Concord Biotech should watch the next few quarters for confirmation of this trend and consult a SEBI-registered advisor before making investment decisions based on these numbers.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions on Concord Biotech Q1 Results FY27
When were the Concord Biotech Q1 results FY27 announced?
Ans. They reflect the quarter ended 30 June 2026, with the data reported as of 31 July 2026. Investors should confirm the exact board meeting date from the official NSE or BSE filing.
What is the PAT in Concord Biotech’s Q1 FY27 results?
Ans. The PAT stood at Rs 56 Cr, compared with Rs 42 Cr in Q1 FY26, a change of +32.55%.
What was the revenue in Concord Biotech’s Q1 FY27 results?
Ans. Revenue came in at Rs 257 Cr for the quarter, a change of +26.23%, compared with Rs 203 Cr in Q1 FY26.
Did Concord Biotech declare a dividend with the Q1 FY27 results?
Ans. Dividend details were not confirmed as part of this results snapshot. Check the latest exchange filing on NSE or BSE, or the Univest Screener, for confirmation.
What is the outlook for Concord Biotech after Q1 FY27?
Ans. Analysts will track whether the growth in revenue and improvement in profit continue into the September 2026 quarter, along with input cost and demand trends in the pharmaceuticals sector.
How did the stock react to Concord Biotech’s Q1 FY27 results?
Ans. Shares traded around Rs 1,444.4 on the NSE, up 1.66% as the numbers came into focus.
Is Concord Biotech a good buy after the Q1 FY27 results?
Ans. The quarter shows a net profit of Rs 56 Cr on revenue of Rs 257 Cr. This article is for educational purposes only and is not investment advice. Consult a SEBI-registered advisor before making any investment decision.
